Trickey A, Nixon E, Christensen H, Finn A, Thomas A, Relton C, Montgomery C, Hemani G, Metz J, Walker JG, Turner K, Kwiatkowska R, Sauchelli S, Danon L, Brooks-Pollock E. University students and staff able to maintain low daily contact numbers during various COVID-19 guideline periods. Epidemiol Infect. 2021 Aug 10;149:e169. doi: 10.1017/S0950268821001618
Wasserman M, Lucas A, Jones D, Wilson M, Hilton B, Vyse A, Madhava H, Brogan A. Dynamic transmission modelling to address infant pneumococcal conjugate vaccine schedule modifications in the UK. Epidemiol Infect. 2018 Oct;146(14):1797-806. doi: 10.1017/S095026881800198X
Wilson M, Lucas A, Cameron A, Luo M. Budget impact of adding vedolizumab to a health plan formulary as a first-line biologic option for ulcerative colitis and crohn's disease. Am Health Drug Benefits. 2018 Jul;11(5):253-62.
Buck PO, Meyers JL, Gordon LD, Parikh R, Kurosky SK, Davis KL. Economic burden of diagnosed pertussis among individuals with asthma or chronic obstructive pulmonary disease in the USA: an analysis of administrative claims. Epidemiol Infect. 2017 Jul;145(10):2109-21. doi: 10.1017/S0950268817000887.
Harris JB, Ward MA, Schwab P. Is response-guided therapy being applied in the clinical setting? The hepatitis C example. Am Health Drug Benefits. 2015 Feb;8(1):22-8.
Sacco P, Capkun-Niggli G, Zhang X, Jose R. The economic burden of fragile x syndrome: healthcare resource utilization in the United States. Am Health Drug Benefits. 2013 Mar;6(2):73-83.
Lennert B, Bibeau W, Farrelly E, Sacco P, Schoor T. Assessment of treatment patterns and patient outcomes in levodopa-induced dyskinesias (ASTROID): a US chart review study. Am Health Drug Benefits. 2012 Sep;5(6):347-58.
Poulos C, Riewpaiboon A, Stewart JF, Clemens J, Guh S, Agtini M, Sur D, Islam Z, Lucas M, Whittington D. Costs of illness due to endemic cholera. Epidemiol Infect. 2012 Mar 1;140(03):500-9.